PTNPALATIN TECHNOLOGIES INC

NYSE palatin.com


$ 1.77 $ -0.05 (-2.75 %)    

Monday, 29-Apr-2024 10:12:56 EDT
QQQ $ 432.82 $ -0.33 (-0.08 %)
DIA $ 383.46 $ 0.27 (0.07 %)
SPY $ 510.50 $ 0.24 (0.05 %)
TLT $ 88.80 $ 0.14 (0.16 %)
GLD $ 216.48 $ 0.43 (0.2 %)
$ 1.82
$ 1.85
$ 0.00 x 0
$ 0.00 x 0
$ 1.77 - $ 1.85
$ 1.43 - $ 5.65
118,925
na
29.37M
$ 1.04
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-14-2024 12-31-2023 10-Q
2 11-14-2023 09-30-2023 10-Q
3 09-28-2023 06-30-2023 10-K
4 05-15-2023 03-31-2023 10-Q
5 02-14-2023 12-31-2022 10-Q
6 11-14-2022 09-30-2022 10-Q
7 09-22-2022 06-30-2022 10-K
8 05-16-2022 03-31-2022 10-Q
9 02-14-2022 12-31-2021 10-Q
10 11-15-2021 09-30-2021 10-Q
11 09-28-2021 06-30-2021 10-K
12 05-14-2021 03-31-2021 10-Q
13 02-16-2021 12-31-2020 10-Q
14 11-16-2020 09-30-2020 10-Q
15 09-25-2020 06-30-2020 10-K
16 05-11-2020 03-31-2020 10-Q
17 02-10-2020 12-31-2019 10-Q
18 11-12-2019 09-30-2019 10-Q
19 09-12-2019 06-30-2019 10-K
20 05-09-2019 03-31-2019 10-Q
21 02-11-2019 12-31-2018 10-Q
22 11-09-2018 09-30-2018 10-Q
23 09-13-2018 06-30-2018 10-K
24 05-14-2018 03-31-2018 10-Q
25 02-12-2018 12-31-2017 10-Q
26 11-13-2017 09-30-2017 10-Q
27 09-25-2017 06-30-2017 10-K
28 05-15-2017 03-31-2017 10-Q
29 02-10-2017 12-31-2016 10-Q
30 11-14-2016 09-30-2016 10-Q
31 09-19-2016 06-30-2016 10-K
32 05-16-2016 03-31-2016 10-Q
33 02-12-2016 12-31-2015 10-Q
34 11-12-2015 09-30-2015 10-Q
35 09-18-2015 06-30-2015 10-K
36 05-12-2015 03-31-2015 10-Q
37 02-12-2015 12-31-2014 10-Q
38 11-14-2014 09-30-2014 10-Q
39 09-12-2014 06-30-2014 10-K
40 05-12-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 palatin-technologies-and-2-other-stocks-under-3-insiders-are-buying

The Dow Jones index closed slightly lower on Thursday. When insiders purchase or sell shares, it indicates their confidence or ...

 palatin-technologies-eyes-growing-6b-dry-eye-disease-market-with-late-stage-study-data

Palatin Technologies unveils Phase 3 PL9643 MELODY-1 trial results for dry eye disease treatment, showcasing statistically sign...

 palatin-announces-phase-3-pl9643-melody-1-dry-eye-disease-ded-clinical-data-results-presented-at-american-society-of-cataract-and-refractive-surgery-ascrs-2024

Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that ...

 why-bumble-shares-are-trading-lower-by-12-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.

 hc-wainwright--co-maintains-buy-on-palatin-techs-adjusts-price-target-to-17

HC Wainwright & Co. analyst Joseph Pantginis maintains Palatin Techs (AMEX:PTN) with a Buy, adjusts target to $17 from $70.

 palatin-technologies-disappointing-data-from-dry-eye-disease-study-stock-plummets

Palatin Technologies' results from PL9643 MELODY-1 Phase 3 trial for dry eye disease. The co-primary endpoints and secondar...

 dow-dips-200-points-tjx-posts-upbeat-sales

U.S. stocks traded lower this morning, with the Dow Jones index falling around 200 points on Wednesday. Following the market o...

 palatin-reports-results-of-pl9643-melody-1-pivotal-phase-3-clinical-trial-in-patients-with-dry-eye-disease-on-an-intent-to-treat-analysis-co-primary-sign-endpoint-and-secondary-sign-endpoints-not-met

On an Intent-to-Treat Analysis, Co-Primary Symptom Endpoint Met, Statistical Significance (P<0.025). PL9643 treatment for th...

 hc-wainwright--co-reiterates-buy-on-palatin-techs-maintains-70-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Palatin Techs (AMEX:PTN) with a Buy and maintains $70 price target.

 palatin-techs-reported-wednesday-q2-2024-gaap-eps-056-misses-020-estimate-sales-203m-miss-630m-estimate

Palatin Techs (AMEX:PTN) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.20) ...

 earnings-scheduled-for-february-15-2024

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on rev...

 earnings-preview-palatin-techs
Earnings Preview: Palatin Techs
02/14/2024 20:02:13

 palatin-announces-10m-registered-direct-offering-of-18m-shares-at-546share

Palatin Technologies, Inc. (NYSE:PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing firs...

 palatin-provides-corporate-update-and-highlights-strategic-priorities-for-calendar-year-2024-completed-asset-sale-to-cosette-pharmaceuticals-for-up-to-171m-12m-upfront-plus-sales-based-milestones-of-up-to-159m

Dry Eye Disease (DED): PL9643 MELODY-1 Phase 3 StudyData Base Lock 2H January 2024Topline Data Readout Expected Early 1Q Calend...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION